Topical Crisaborole in Patients With Alopecia Areata

NCT04299503

Last updated date
Study Location
Tufts Medical Center, Department of Dermatology
Boston, Massachusetts, 02111, United States
Contact
617 636 7462

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

617 636 7462

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alopecia Areata
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
2 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Signed and dated informed consent document indicating the subject has been informed of all aspects of the study.

2. Subject is willing and able to comply with scheduled visits, treatment plan, study drug administration, and other study procedures.

3. Clinical diagnosis of alopecia areata with at least one lesion 1 cm in diameter and no more than 20% of total scalp surface area.

4. Females of child-bearing potential agree to use a reliable method of birth control or remain absent during the study and for at least 4 weeks following the last dose of the assigned treatment.

5. If receiving concomitant medications for any reason, must be on a stable regimen and willing to stay on a stable regimen.

6. All treatments for alopecia areata are prohibited during the course of the study. If subjects received any of the following treatments, the minimum criteria are observed:

- Must be discontinued for at least 12 weeks prior to Baseline:

o Any investigational or experimental therapy or procedure for alopecia areata;

- Exception: Investigational biologics should be discussed with Sponsor to confirm period of discontinuation required. Must be discontinued for at least 8 weeks prior to Baseline:

o Laser or light based alopecia areata treatments

- Must be discontinued for at least 4 weeks prior to Baseline:

- Immunomodulating or immunosuppressive oral medications (corticosteroids, methotrexate, cyclosporine, etc.) Subjects who require these medications during the study (e.g. use of corticosteroids for a chronic obstructive pulmonary disease exacerbation) will be terminated from the study.

- Injections of steroids to alopecia areata areas

- Contact sensitization treatment

- Oral minoxidil

- Patients already taking finesteride for at least 3 months to treat conditions in addition to or other than hair loss (benign prostate hypertrophy, hormonal suppression, etc.) may continue on this medication so long as the dose remains stable throughout the study.

- Must be discontinued for at least 2 weeks prior to Baseline:

- Topical treatments that may affect alopecia areata, e.g., corticosteroids, topical tacrolimus/pimecrolimus, retinoids. Use of these medications in non-AA areas, for non-AA conditions is allowed.

- Hair regrowth products containing minoxidil

- Use of any prior and concomitant therapy not listed above which, in the opinion of the PI may interfere with the objective of the study, within 60 days prior to the Screening Visit is prohibited

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Other skin conditions that, in the opinion of the PI would interfere with evaluation
of alopecia areata. Conditions may include other types of hair loss, including discoid
lupus, lichen planus pilaris, frontal fibrosing alopecia, cicatricial alopecia, and
trichotillomania (hair pulling).


2. Pregnant/breastfeeding females, or females of childbearing potential not using highly
effective contraception. Women of childbearing potential must test negative for
pregnancy and use contraception for at least four weeks after last dose of drug.


3. Current or recent history of clinically significant medical or psychiatric condition,
which, in the judgment of the principal investigator, may increase risk associated
with the study participation or drug administration. Examples include, but are not
limited to, recent infections or injuries of the scalp.


4. Have a history of infection requiring parenteral or oral or topical antimicrobial
therapy within 2 weeks prior to baseline.


5. Received a prohibited concomitant medication within 7 days or 5 half-lives (whichever
is longer) prior to baseline visit.


6. Subjects who have had an allergic reaction (e.g. urticarial, anaphylactic) to
crisaborole will be excluded.


7. Participated in a trial for a topical or oral JAK inhibitor. JAK inhibitors are
thought to improve alopecia areata, and sometimes the effects of JAK inhibitors can
last long after treatment is completed. Past treatment with these agents could
confound the results of crisaborole's effectiveness for alopecia.


8. Is currently on an oral PDE4 inhibitor or oral JAK inhibitor. PDE4 inhibitors and JAK
inhibitors have been theorized to improve alopecia. Treatment with these agents could
confound our results on the effectiveness of crisaborole for alopecia areata.


9. Have participated in other research studies of investigational products within 4 weeks
or 5 half-lives (whichever is longer) of the investigational product prior to
baseline. Subjects cannot participate in studies of other investigational or
experimental therapies or procedures at any time during their participation in this
study.


10. Subjects who are investigational site staff members or relatives of those site staff
members or subjects who are Sponsor employees directly involved in the conduct of the
trial.


11. In the opinion of the investigator or Sponsor, the subject is inappropriate for entry
into this study, or unwilling/unable to comply with study procedures and lifestyle
guidelines.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Alopecia AreataTopical Crisaborole in Patients With Alopecia Areata
NCT04299503
  1. Boston, Massachusetts
ALL GENDERS
2 Years+
years
MULTIPLE SITES
Alopecia AreataPLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA
NCT04517864
  1. Huntington Beach, California
  2. Boca Raton, Florida
  3. Hollywood, Florida
  4. Jacksonville, Florida
  5. Jacksonville, Florida
  6. Miami, Florida
  7. Miramar, Florida
  8. Plantation, Florida
  9. Raleigh, North Carolina
  10. Houston, Texas
  11. Lynchburg, Virginia
  12. Markham, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Alopecia AreataLong-Term PF-06651600 for the Treatment of Alopecia Areata
NCT04006457
  1. New York, New York
  2. San Antonio, Texas
  3. Medellin, Antioquia
  4. Praha 8,
  5. Debrecen,
  6. Bialystok,
  7. Osielsko,
  8. Wroclaw,
  9. Wroclaw,
  10. Madrid,
  11. Valencia,
  12. Birmingham, Alabama
  13. Beverly Hills, California
  14. Irvine, California
  15. Murrieta, California
  16. San Francisco, California
  17. San Francisco, California
  18. Santa Ana, California
  19. Aurora, Colorado
  20. Aurora, Colorado
  21. New Haven, Connecticut
  22. New Haven, Connecticut
  23. New Haven, Connecticut
  24. Washington, District of Columbia
  25. Washington, District of Columbia
  26. Washington, District of Columbia
  27. Washington, District of Columbia
  28. Washington, District of Columbia
  29. Boynton Beach, Florida
  30. Orange Park, Florida
  31. Tampa, Florida
  32. Meridian, Idaho
  33. Chicago, Illinois
  34. Chicago, Illinois
  35. Chicago, Illinois
  36. Chicago, Illinois
  37. Chicago, Illinois
  38. Oakbrook Terrace, Illinois
  39. Skokie, Illinois
  40. Springfield, Illinois
  41. Indianapolis, Indiana
  42. Iowa City, Iowa
  43. Chevy Chase, Maryland
  44. Boston, Massachusetts
  45. Minneapolis, Minnesota
  46. Minneapolis, Minnesota
  47. Omaha, Nebraska
  48. Verona, New Jersey
  49. New York, New York
  50. New York, New York
  51. New York, New York
  52. New York, New York
  53. Chapel Hill, North Carolina
  54. Chapel Hill, North Carolina
  55. Chapel Hill, North Carolina
  56. Cleveland, Ohio
  57. Tulsa, Oklahoma
  58. Portland, Oregon
  59. Houston, Texas
  60. Vienna, Virginia
  61. Caba,
  62. Caba,
  63. Caba,
  64. Kogarah, New South Wales
  65. Kogarah, New South Wales
  66. Benowa, Queensland
  67. Woolloongabba, Queensland
  68. Carlton, Victoria
  69. East Melbourne, Victoria
  70. Parkville, Victoria
  71. Parkville, Victoria
  72. Winnipeg, Manitoba
  73. London, Ontario
  74. Markham, Ontario
  75. Oakville, Ontario
  76. Peterborough, Ontario
  77. Richmond Hill, Ontario
  78. Sudbury, Ontario
  79. Sudbury, Ontario
  80. Toronto, Ontario
  81. Montreal, Quebec
  82. Quebec,
  83. Santiago, LAS Condes
  84. Santiago, Recoleta
  85. Vina del Mar, Valparaiso
  86. Santiago, Vitacura
  87. Medellin, Antioquia
  88. Bogota D.C.,
  89. Nachod,
  90. Praha 10,
  91. Praha 1,
  92. Bad Bentheim,
  93. Berlin,
  94. Budapest,
  95. Gyongyos,
  96. Nagoya, Aichi
  97. Sendai, Miyagi
  98. Osaka-City, Osaka
  99. Hamamatsu, Shizuoka
  100. Koto-ku, Tokyo
  101. Mitaka-shi, Tokyo
  102. Tokyo,
  103. Busan,
  104. Seoul,
  105. Seoul,
  106. Monterrey, Nuevo LEON
  107. Veracruz,
  108. Veracruz,
  109. Grodzisk Mazowiecki,
  110. Krakow,
  111. Lodz,
  112. Ostrowiec Swietokrzyski,
  113. Szczecin,
  114. Warszawa,
  115. Warszawa,
  116. Warszawa,
  117. Warszawa,
  118. Wroclaw,
  119. Wroclaw,
  120. Chelyabinsk,
  121. Kirov,
  122. Moscow,
  123. Moscow,
  124. Rostov-on-Don,
  125. Saint Petersburg,,
  126. Saint Petersburg,
  127. Saint Petersburg,
  128. Yaroslavl,
  129. Badalona, Barcelona
  130. Barcelona,
  131. Cordoba,
  132. Madrid,
  133. Taichung, R.o.c.
  134. Kaohsiung City,
  135. Kaohsiung,
  136. New Taipei City,
  137. Taipei,
  138. Taoyuan City,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
Alopecia AreataPF-06651600 for the Treatment of Alopecia Areata
NCT03732807
  1. Beverly Hills, California
  2. Richmond Hill, Ontario
  3. Birmingham, Alabama
  4. Irvine, California
  5. Murrieta, California
  6. San Francisco, California
  7. San Francisco, California
  8. Santa Ana, California
  9. Aurora, Colorado
  10. New Haven, Connecticut
  11. New Haven, Connecticut
  12. New Haven, Connecticut
  13. New Haven, Connecticut
  14. Washington, District of Columbia
  15. Washington, District of Columbia
  16. Washington, District of Columbia
  17. Boynton Beach, Florida
  18. Orange Park, Florida
  19. Tampa, Florida
  20. Meridian, Idaho
  21. Chicago, Illinois
  22. Chicago, Illinois
  23. Chicago, Illinois
  24. Chicago, Illinois
  25. Skokie, Illinois
  26. Springfield, Illinois
  27. Indianapolis, Indiana
  28. Iowa City, Iowa
  29. Iowa City, Iowa
  30. Chevy Chase, Maryland
  31. Boston, Massachusetts
  32. Minneapolis, Minnesota
  33. Minneapolis, Minnesota
  34. Omaha, Nebraska
  35. Verona, New Jersey
  36. New York, New York
  37. New York, New York
  38. New York, New York
  39. New York, New York
  40. Chapel Hill, North Carolina
  41. Chapel Hill, North Carolina
  42. Chapel Hill, North Carolina
  43. Cleveland, Ohio
  44. Tulsa, Oklahoma
  45. Houston, Texas
  46. Caba,
  47. Caba,
  48. Kogarah, New South Wales
  49. Kogarah, New South Wales
  50. Benowa, Queensland
  51. Woolloongabba, Queensland
  52. Carlton, Victoria
  53. East Melbourne, Victoria
  54. Parkville, Victoria
  55. Parkville, Victoria
  56. Winnipeg, Manitoba
  57. Halifax, Nova Scotia
  58. London, Ontario
  59. Markham, Ontario
  60. Oakville, Ontario
  61. Peterborough, Ontario
  62. Sudbury, Ontario
  63. Sudbury, Ontario
  64. Toronto, Ontario
  65. Montreal, Quebec
  66. Quebec,
  67. Santiago, LAS Condes
  68. Santiago, Recoleta
  69. Santiago, Region Metropolitana
  70. Vina del Mar, Valparaiso
  71. Beijing, Beijing
  72. Beijing, Beijing
  73. Beijing, Beijing
  74. Guangzhou, Guangdong
  75. Shenzhen, Guangdong
  76. Wuhan, Hubei
  77. Nanjing, Jiangsu
  78. Shanghai, Shanghai
  79. Hangzhou, Zhejiang
  80. Hangzhou, Zhejiang
  81. Shanghai,
  82. Medellin, Antioquia
  83. Medellin, Antioquia
  84. Bogota, D.c.
  85. Brno,
  86. Brno,
  87. Nachod,
  88. Náchod,
  89. Olomouc,
  90. Praha 10,
  91. Praha 1,
  92. Praha 8 - Liben,
  93. Praha 8- Liben,
  94. Praha2,
  95. Bad Bentheim,
  96. Berlin,
  97. Erlangen,
  98. Frankfurt am Main,
  99. Luebeck,
  100. Luebeck,
  101. Muenster,
  102. Budapest,
  103. Debrecen,
  104. Gyongyos,
  105. Szeged,
  106. Nagoya, Aichi
  107. Sendai, Miyagi
  108. Hamamatsu, Shizuoka
  109. Koto-ku, Tokyo
  110. Shinjuku-ku, Tokyo
  111. Osaka,
  112. Busan,
  113. Seoul,
  114. Seoul,
  115. Veracruz,
  116. Krakow,
  117. Lodz,
  118. Szczecin,
  119. Warszawa,
  120. Warszawa,
  121. Wroclaw,
  122. Chelyabinsk,
  123. Kirov,
  124. Moscow,
  125. Moscow,
  126. Rostov-on-Don,
  127. Saint Petersburg,,
  128. Saint Petersburg,
  129. Saint Petersburg,
  130. Yaroslavl,
  131. Badalona, Barcelona
  132. Barcelona,
  133. Barcelona,
  134. Barcelona,
  135. Córdoba,
  136. Madrid,
  137. Madrid,
  138. Valencia,
  139. Kaohsiung City,
  140. Kaohsiung,
  141. New Taipei City,
  142. New Taipei City,
  143. Taichung,
  144. Taichung,
  145. Taipei,
  146. Taoyuan City,
  147. Brighton, EAST Sussex
  148. Southampton, Hampshire
  149. Dundee,
  150. Glasgow,
  151. Hampshire,
  152. London,
  153. London,
ALL GENDERS
12 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Topical Crisaborole in Patients With Alopecia Areata
Official Title  ICMJE Phase 2 Double Blind Randomized Placebo Controlled Trial of Topical Crisaborole in Patients With Mild-to-Moderate Alopecia Areata
Brief Summary The aim of this study is to determine whether topical crisaborole improves hair growth in alopecia areata.
Detailed Description Each individual will be enrolled in the study for 24 weeks. Following a 28 days screening period, eligible subjects will be randomized in a 1:1 ratio to receive either crisaborole 2% ointment or matching placebo for 12 weeks. The primary endpoint is assessed at week 12. At the week 12 visit, all subjects will enter the open label treatment period where they will all receive crisaborole 2% ointment for an additional 12 weeks, with the last study visit taking place on week 24.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:
Double-Blind Period: Weeks 0-12; Open-Label Period: Weeks 12-24
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
All site staff will be masked with the exception of pharmacy staff
Primary Purpose: Treatment
Condition  ICMJE Alopecia Areata
Intervention  ICMJE
  • Drug: Crisaborole Topical Ointment
    For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
    Other Name: Eucrisa
  • Drug: Placebo Topical Ointment
    For every 10% of scalp affected, approximately ½ finger tip of study drug will be needed to cover the area with a thin layer. After the first application at baseline, the tubes will be weighed to determine the dose needed to cover the affected area. This will be the subject's target dose throughout the study
    Other Name: Placebo
Study Arms  ICMJE
  • Active Comparator: Crisaborole
    ointment applied topically in the morning and in the evening
    Intervention: Drug: Crisaborole Topical Ointment
  • Placebo Comparator: Placebo
    ointment applied topically in the morning and in the evening
    Intervention: Drug: Placebo Topical Ointment
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: March 4, 2020)
60
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2021
Estimated Primary Completion Date March 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Signed and dated informed consent document indicating the subject has been informed of all aspects of the study.
  2. Subject is willing and able to comply with scheduled visits, treatment plan, study drug administration, and other study procedures.
  3. Clinical diagnosis of alopecia areata with at least one lesion 1 cm in diameter and no more than 20% of total scalp surface area.
  4. Females of child-bearing potential agree to use a reliable method of birth control or remain absent during the study and for at least 4 weeks following the last dose of the assigned treatment.
  5. If receiving concomitant medications for any reason, must be on a stable regimen and willing to stay on a stable regimen.
  6. All treatments for alopecia areata are prohibited during the course of the study. If subjects received any of the following treatments, the minimum criteria are observed:

    • Must be discontinued for at least 12 weeks prior to Baseline:

      o Any investigational or experimental therapy or procedure for alopecia areata;

    • Exception: Investigational biologics should be discussed with Sponsor to confirm period of discontinuation required. Must be discontinued for at least 8 weeks prior to Baseline:

      o Laser or light based alopecia areata treatments

    • Must be discontinued for at least 4 weeks prior to Baseline:

      • Immunomodulating or immunosuppressive oral medications (corticosteroids, methotrexate, cyclosporine, etc.) Subjects who require these medications during the study (e.g. use of corticosteroids for a chronic obstructive pulmonary disease exacerbation) will be terminated from the study.
      • Injections of steroids to alopecia areata areas
      • Contact sensitization treatment
      • Oral minoxidil
      • Patients already taking finesteride for at least 3 months to treat conditions in addition to or other than hair loss (benign prostate hypertrophy, hormonal suppression, etc.) may continue on this medication so long as the dose remains stable throughout the study.
    • Must be discontinued for at least 2 weeks prior to Baseline:

      • Topical treatments that may affect alopecia areata, e.g., corticosteroids, topical tacrolimus/pimecrolimus, retinoids. Use of these medications in non-AA areas, for non-AA conditions is allowed.
      • Hair regrowth products containing minoxidil
    • Use of any prior and concomitant therapy not listed above which, in the opinion of the PI may interfere with the objective of the study, within 60 days prior to the Screening Visit is prohibited

Exclusion Criteria:

  1. Other skin conditions that, in the opinion of the PI would interfere with evaluation of alopecia areata. Conditions may include other types of hair loss, including discoid lupus, lichen planus pilaris, frontal fibrosing alopecia, cicatricial alopecia, and trichotillomania (hair pulling).
  2. Pregnant/breastfeeding females, or females of childbearing potential not using highly effective contraception. Women of childbearing potential must test negative for pregnancy and use contraception for at least four weeks after last dose of drug.
  3. Current or recent history of clinically significant medical or psychiatric condition, which, in the judgment of the principal investigator, may increase risk associated with the study participation or drug administration. Examples include, but are not limited to, recent infections or injuries of the scalp.
  4. Have a history of infection requiring parenteral or oral or topical antimicrobial therapy within 2 weeks prior to baseline.
  5. Received a prohibited concomitant medication within 7 days or 5 half-lives (whichever is longer) prior to baseline visit.
  6. Subjects who have had an allergic reaction (e.g. urticarial, anaphylactic) to crisaborole will be excluded.
  7. Participated in a trial for a topical or oral JAK inhibitor. JAK inhibitors are thought to improve alopecia areata, and sometimes the effects of JAK inhibitors can last long after treatment is completed. Past treatment with these agents could confound the results of crisaborole's effectiveness for alopecia.
  8. Is currently on an oral PDE4 inhibitor or oral JAK inhibitor. PDE4 inhibitors and JAK inhibitors have been theorized to improve alopecia. Treatment with these agents could confound our results on the effectiveness of crisaborole for alopecia areata.
  9. Have participated in other research studies of investigational products within 4 weeks or 5 half-lives (whichever is longer) of the investigational product prior to baseline. Subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study.
  10. Subjects who are investigational site staff members or relatives of those site staff members or subjects who are Sponsor employees directly involved in the conduct of the trial.
  11. In the opinion of the investigator or Sponsor, the subject is inappropriate for entry into this study, or unwilling/unable to comply with study procedures and lifestyle guidelines.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 2 Years and older   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Nicole M Dumont617 636 7462[email protected]
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04299503
Other Study ID Numbers  ICMJE 13289
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD:No
Responsible Party Tufts Medical Center
Study Sponsor  ICMJE Tufts Medical Center
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:David Rosmarin, MDTufts Medical Center
PRS Account Tufts Medical Center
Verification Date August 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP